Here, we have utilized endometrial cancer cell lines harboring driver mutations in FGFR2 (Byron et al., 2008, Dutt et al., 2008, Pollock et al., 2007) as a platform to identify mechanisms of tyrosine kinase inhibitor (TKI) resistance. This evidence concerns the gene FGFR2 and endometrial cancer.